Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06519617
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
None
First Post:
2024-07-13
Brief Title:
Study on Optimization and Evaluation of Integrated Chinese and Western Medicine for pSS Glandular Damage
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Study on Optimization and Evaluation of Integrated Chinese and Western Medicine for Primary Sjogrens Syndrome Glandular Damage
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
ChatGPT In a randomized controlled trial 136 patients with primary Sjögrens syndrome pSS meeting the inclusion criteria were enrolled and randomly divided into two groups of 68 each The treatment group received an optimized program combining Chinese and Western medicine for pSS glandular injury while the control group received a conventional program for pSS glandular damage The primary efficacy endpoint was the 12-week non-stimulated salivary flow rate UWS score Secondary efficacy endpoints included the glandular damage Visual Analog Scale VAS scores the European Sjögrens Syndrome Patient Reported Index ESSPRI among others The treatment course lasted 12 weeks The efficacy and safety of the optimized program for pSS glandular injury were evaluated by comparing within and between groups before and after treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None